Cargando…
Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen -4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1B...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094423/ https://www.ncbi.nlm.nih.gov/pubmed/25013914 http://dx.doi.org/10.1371/journal.pone.0101764 |
_version_ | 1782325822705631232 |
---|---|
author | Belcaid, Zineb Phallen, Jillian A. Zeng, Jing See, Alfred P. Mathios, Dimitrios Gottschalk, Chelsea Nicholas, Sarah Kellett, Meghan Ruzevick, Jacob Jackson, Christopher Albesiano, Emilia Durham, Nicholas M. Ye, Xiaobu Tran, Phuoc T. Tyler, Betty Wong, John W. Brem, Henry Pardoll, Drew M. Drake, Charles G. Lim, Michael |
author_facet | Belcaid, Zineb Phallen, Jillian A. Zeng, Jing See, Alfred P. Mathios, Dimitrios Gottschalk, Chelsea Nicholas, Sarah Kellett, Meghan Ruzevick, Jacob Jackson, Christopher Albesiano, Emilia Durham, Nicholas M. Ye, Xiaobu Tran, Phuoc T. Tyler, Betty Wong, John W. Brem, Henry Pardoll, Drew M. Drake, Charles G. Lim, Michael |
author_sort | Belcaid, Zineb |
collection | PubMed |
description | BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen -4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1BB (CD137) is expressed by activated T lymphocytes and served as a co-stimulatory signal, which promotes cytotoxic function. Here, we evaluate a combination immunotherapy regimen involving 4-1BB activation, CTLA-4 blockade, and focal radiation therapy in an immune-competent intracranial GBM model. METHODS: GL261-luciferace cells were stereotactically implanted in the striatum of C57BL/6 mice. Mice were treated with a triple therapy regimen consisted of 4-1BB agonist antibodies, CTLA-4 blocking antibodies, and focal radiation therapy using a small animal radiation research platform and mice were followed for survival. Numbers of brain-infiltrating lymphocytes were analyzed by FACS analysis. CD4 or CD8 depleting antibodies were administered to determine the relative contribution of T helper and cytotoxic T cells in this regimen. To evaluate the ability of this immunotherapy to generate an antigen-specific memory response, long-term survivors were re-challenged with GL261 glioma en B16 melanoma flank tumors. RESULTS: Mice treated with triple therapy had increased survival compared to mice treated with focal radiation therapy and immunotherapy with 4-1BB activation and CTLA-4 blockade. Animals treated with triple therapy exhibited at least 50% long-term tumor free survival. Treatment with triple therapy resulted in a higher density of CD4(+) and CD8(+) tumor infiltrating lymphocytes. Mechanistically, depletion of CD4(+) T cells abrogated the antitumor efficacy of triple therapy, while depletion of CD8(+) T cells had no effect on the treatment response. CONCLUSION: Combination therapy with 4-1BB activation and CTLA-4 blockade in the setting of focal radiation therapy improves survival in an orthotopic mouse model of glioma by a CD4(+) T cell dependent mechanism and generates antigen-specific memory. |
format | Online Article Text |
id | pubmed-4094423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40944232014-07-15 Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model Belcaid, Zineb Phallen, Jillian A. Zeng, Jing See, Alfred P. Mathios, Dimitrios Gottschalk, Chelsea Nicholas, Sarah Kellett, Meghan Ruzevick, Jacob Jackson, Christopher Albesiano, Emilia Durham, Nicholas M. Ye, Xiaobu Tran, Phuoc T. Tyler, Betty Wong, John W. Brem, Henry Pardoll, Drew M. Drake, Charles G. Lim, Michael PLoS One Research Article BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor in adults and is associated with a poor prognosis. Cytotoxic T lymphocyte antigen -4 (CTLA-4) blocking antibodies have demonstrated an ability to generate robust antitumor immune responses against a variety of solid tumors. 4-1BB (CD137) is expressed by activated T lymphocytes and served as a co-stimulatory signal, which promotes cytotoxic function. Here, we evaluate a combination immunotherapy regimen involving 4-1BB activation, CTLA-4 blockade, and focal radiation therapy in an immune-competent intracranial GBM model. METHODS: GL261-luciferace cells were stereotactically implanted in the striatum of C57BL/6 mice. Mice were treated with a triple therapy regimen consisted of 4-1BB agonist antibodies, CTLA-4 blocking antibodies, and focal radiation therapy using a small animal radiation research platform and mice were followed for survival. Numbers of brain-infiltrating lymphocytes were analyzed by FACS analysis. CD4 or CD8 depleting antibodies were administered to determine the relative contribution of T helper and cytotoxic T cells in this regimen. To evaluate the ability of this immunotherapy to generate an antigen-specific memory response, long-term survivors were re-challenged with GL261 glioma en B16 melanoma flank tumors. RESULTS: Mice treated with triple therapy had increased survival compared to mice treated with focal radiation therapy and immunotherapy with 4-1BB activation and CTLA-4 blockade. Animals treated with triple therapy exhibited at least 50% long-term tumor free survival. Treatment with triple therapy resulted in a higher density of CD4(+) and CD8(+) tumor infiltrating lymphocytes. Mechanistically, depletion of CD4(+) T cells abrogated the antitumor efficacy of triple therapy, while depletion of CD8(+) T cells had no effect on the treatment response. CONCLUSION: Combination therapy with 4-1BB activation and CTLA-4 blockade in the setting of focal radiation therapy improves survival in an orthotopic mouse model of glioma by a CD4(+) T cell dependent mechanism and generates antigen-specific memory. Public Library of Science 2014-07-11 /pmc/articles/PMC4094423/ /pubmed/25013914 http://dx.doi.org/10.1371/journal.pone.0101764 Text en © 2014 Belcaid et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Belcaid, Zineb Phallen, Jillian A. Zeng, Jing See, Alfred P. Mathios, Dimitrios Gottschalk, Chelsea Nicholas, Sarah Kellett, Meghan Ruzevick, Jacob Jackson, Christopher Albesiano, Emilia Durham, Nicholas M. Ye, Xiaobu Tran, Phuoc T. Tyler, Betty Wong, John W. Brem, Henry Pardoll, Drew M. Drake, Charles G. Lim, Michael Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title_full | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title_fullStr | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title_full_unstemmed | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title_short | Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model |
title_sort | focal radiation therapy combined with 4-1bb activation and ctla-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094423/ https://www.ncbi.nlm.nih.gov/pubmed/25013914 http://dx.doi.org/10.1371/journal.pone.0101764 |
work_keys_str_mv | AT belcaidzineb focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT phallenjilliana focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT zengjing focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT seealfredp focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT mathiosdimitrios focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT gottschalkchelsea focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT nicholassarah focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT kellettmeghan focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT ruzevickjacob focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT jacksonchristopher focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT albesianoemilia focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT durhamnicholasm focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT yexiaobu focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT tranphuoct focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT tylerbetty focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT wongjohnw focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT bremhenry focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT pardolldrewm focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT drakecharlesg focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel AT limmichael focalradiationtherapycombinedwith41bbactivationandctla4blockadeyieldslongtermsurvivalandaprotectiveantigenspecificmemoryresponseinamurinegliomamodel |